CytoDel Overview

  • Year Founded
  • 2012

Year Founded

  • Status
  • Private

  • Employees
  • 5

Employees

  • Latest Deal Type
  • Grant

  • Latest Deal Amount
  • $295K

  • Investors
  • 4

CytoDel General Information

Description

Operator of a biotechnology platform intended to produce recombinant derivatives of botulinum neurotoxin (BoNT). The company's platform manipulates the BoNT molecule into a drug delivery vehicle that can deliver therapeutic molecules to the inside of neurons with important implications, enabling medical researchers to develop drugs and facilitate the treatment of nervous system disorders, chronic pain, and neurodegenerative diseases.

Contact Information

Website
www.cytodel.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 423 West 127th Street
  • New York, NY 10027
  • United States
+1 (501)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Life Sciences
Corporate Office
  • 423 West 127th Street
  • New York, NY 10027
  • United States
+1 (501)

CytoDel Timeline

2022202320242025
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

CytoDel Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Grant 01-Jan-2023 $295K Completed Generating Revenue
6. Grant 01-Mar-2022 Completed Generating Revenue
5. Accelerator/Incubator Completed Generating Revenue
4. Later Stage VC (Series A) 16-Jan-2018 Completed Generating Revenue
3. Grant 01-Jul-2017 Completed Generating Revenue
2. Grant 01-Jan-2014 $224K Completed Generating Revenue
1. Accelerator/Incubator 13-Dec-2013 Completed Generating Revenue
To view CytoDel’s complete valuation and funding history, request access »

CytoDel Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series A-1
Series A-2
To view CytoDel’s complete cap table history, request access »

CytoDel Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a biotechnology platform intended to produce recombinant derivatives of botulinum neurotoxin (BoNT). The com
Drug Discovery
New York, NY
5 As of 2024

Thousand Oaks, CA
 

Cambridge, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

CytoDel Competitors (5)

One of CytoDel’s 5 competitors is Amgen, a Formerly PE-Backed company based in Thousand Oaks, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Amgen Formerly PE-Backed Thousand Oaks, CA
Biogen Formerly VC-backed Cambridge, MA
Eli Lilly Corporation Indianapolis, IN
AbbVie Corporation North Chicago, IL
Merz Pharma Corporation Frankfurt, Germany
You’re viewing 5 of 5 competitors. Get the full list »

CytoDel Patents

  • 1

    Total Documents Applications and Grants

  • Total Patents Families

  • Granted

  • 1

    Pending

  • Expiring in next 12 mo

CytoDel Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20220333091-A1 Recombinant botulinum neurotoxin with improved safety margin and reduced immunogenicity Pending 30-Sep-2019

CytoDel Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

CytoDel Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds
Kairos Ventures Venture Capital Minority
NYU Entrepreneurial Institute Accelerator/Incubator Minority
National Institutes of Health Government
U.S. Department of Health and Human Services Government
To view CytoDel’s complete investors history, request access »

Ready to get started?

Request a free trial

CytoDel FAQs

  • When was CytoDel founded?

    CytoDel was founded in 2012.

  • Where is CytoDel headquartered?

    CytoDel is headquartered in New York, NY.

  • What is the size of CytoDel?

    CytoDel has 5 total employees.

  • What industry is CytoDel in?

    CytoDel’s primary industry is Drug Discovery.

  • Is CytoDel a private or public company?

    CytoDel is a Private company.

  • What is CytoDel’s current revenue?

    The current revenue for CytoDel is .

  • How much funding has CytoDel raised over time?

    CytoDel has raised $3.9M.

  • Who are CytoDel’s investors?

    Kairos Ventures, NYU Entrepreneurial Institute, National Institutes of Health, and U.S. Department of Health and Human Services have invested in CytoDel.

  • Who are CytoDel’s competitors?

    Amgen, Biogen, Eli Lilly, AbbVie, and Merz Pharma are competitors of CytoDel.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »